Entry into Latin America's Largest Pharmaceutical Market
"First Domestically Developed P-CAB Drug to Launch in Brazil"

HK inno.N said on November 17 that K-CAB, its treatment for gastroesophageal reflux disease containing tegoprazan, recently received marketing approval from Brazil's National Health Surveillance Agency (ANVISA).


With this approval, K-CAB is set to become the first domestically developed P-CAB drug to launch in Brazil. Brazil is the largest pharmaceutical market in Latin America, and its local market for drugs used to treat peptic ulcers was valued at approximately KRW 1.1 trillion last year. HK inno.N plans to use the approval to expand K-CAB's presence in the local market and strengthen its business competitiveness across Latin America.


HK inno.N's K-CAB series of treatments for gastroesophageal reflux disease. HK inno.N

HK inno.N's K-CAB series of treatments for gastroesophageal reflux disease. HK inno.N

View original image

The active pharmaceutical ingredient for K-CAB supplied to Brazil will be manufactured at HK inno.N's Daeso Plant. Last year, the plant received Good Manufacturing Practice (GMP) certification from Brazil's ANVISA for the manufacture and quality control of tegoprazan active pharmaceutical ingredients.


HK inno.N signed a technology transfer agreement for K-CAB with Brazilian pharmaceutical company Eurofarma in 2022. K-CAB is expected to be sold in Brazil under the brand name TREV.



HK inno.N CEO Kwak Dal-won said, "We will work closely with our local partner to do our best to establish K-CAB as a new treatment option for patients in Brazil."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing